Structural plasticity, selective ligandability, and the challenge of functional redundancy in TIF1 bromodomain mediated tumorigenesis

The transcriptional intermediary factor 1 (TIF1) subfamily of bromodomain-containing proteins, comprising TIF1α (TRIM24), TIF1β (TRIM28/KAP1), TIF1γ (TRIM33), and TRIM66, has emerged as a compelling group of epigenetic regulators with increasingly recognized therapeutic relevance in oncology. These proteins, characterized by their unique tandem PHD-bromodomain architecture, function as context-dependent epigenetic readers and coregulators, critically influencing tumorigenesis across diverse cancers including breast, prostate, and non-small cell lung carcinoma. While bromodomain and extra-terminal (BET) inhibitors have validated the therapeutic potential of targeting acetyl-lysine recognition, the TIF1 family remains relatively underexplored, hindered by functional complexity, selectivity challenges and a scarcity of selective chemical probes. This review focuses on the structural and functional basis of TIF1 bromodomain targeting in cancer, examining the oncogenic roles of individual TIF1 family members and the contribution of their bromodomains to chromatin remodeling and disease progression. We further discuss how emerging artificial intelligence and machine learning approaches in structure-guided virtual screening, predictive selectivity modeling, de novo ligand generation, and the creation of novel modalities such as PROTACs may accelerate TIF1 inhibitor discovery. We also evaluate current limitations in the field, including poor bromodomain selectivity, limited in vivo validation, and the absence of clinically advanced TIF1-targeted compounds. Finally, we propose a roadmap for developing novel TIF1 bromodomain inhibitors, emphasizing the integration of computational and experimental approaches guided by AI-assisted discovery pipelines to advance first-in-class TIF1-directed therapies in precision oncology.